EZH2 and neoplasm: Similarly, a study by Gonzalez ME et al. demonstrated that EZH2 KD in primary tumor cells isolated from patients with triple-negative (TN) invasive breast carcinoma, as well as in breast cancer cell lines, significantly reduced the proportion of CD44+/CD24− and ALDH1+ cells compared with controls.